Antineoplastics/rituximab
1
Reactions 1310 - 17 Jul 2010 S Antineoplastics/rituximab Hepatitis C infection: case report A 39-year-old woman received eight courses of rituximab-based chemotherapy with R-CHOP [details of regimen not stated], followed by maintenance rituximab treatment for B-cell follicular lymphoma [dosages and route not stated]. She presented with fatigue and elevated bilirubin levels 1.5 years after starting maintenance therapy. Subsequent laboratory findings showed elevated AST. ALT, GGT and alkaline phosphatase levels, indicating hepatic cytolysis. Lymphoma relapse was suspected, but rituximab was withdrawn and she was monitored for a possible viral infection. Within 3 weeks, she developed extreme fatigue, generalised oedema and jaundice; multiple ascites were also noted. Her laboratory parameters had worsened, and repeat viral tests confirmed hepatitis C virus. Treatment was initiated with interferon-α, ursodeoxycholic acid and human albumin. Her condition had improved 3 weeks later. Author comment: "We consider this a case of severe hepatitis C viral infection at a patient with compromised immunity due to prior chemotherapy and monoclonal antibody therapy." Benedek I, et al. SEVERE CASE OF HEPATITIS C INFECTION AT A FOLLICULAR NON-HODGKIN LYMPHOMA PATIENT UNDER RITUXIMAB MAINTENANCE THERAPY. 15th Congress of the European Haematology Association : abstr. 1617, 10 Jun 2010. Available from: URL: http:// eha.eurocongres.com/15th - Romania 803026541 1 Reactions 17 Jul 2010 No. 1310 0114-9954/10/1310-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics/rituximab
Reactions 1310 - 17 Jul 2010
SAntineoplastics/rituximab
Hepatitis C infection: case reportA 39-year-old woman received eight courses of
rituximab-based chemotherapy with R-CHOP [details ofregimen not stated], followed by maintenance rituximabtreatment for B-cell follicular lymphoma [dosages and routenot stated]. She presented with fatigue and elevatedbilirubin levels 1.5 years after starting maintenancetherapy. Subsequent laboratory findings showed elevatedAST. ALT, GGT and alkaline phosphatase levels, indicatinghepatic cytolysis. Lymphoma relapse was suspected, butrituximab was withdrawn and she was monitored for apossible viral infection. Within 3 weeks, she developedextreme fatigue, generalised oedema and jaundice;multiple ascites were also noted. Her laboratoryparameters had worsened, and repeat viral tests confirmedhepatitis C virus. Treatment was initiated with interferon-α,ursodeoxycholic acid and human albumin. Her conditionhad improved 3 weeks later.
Author comment: "We consider this a case of severehepatitis C viral infection at a patient with compromisedimmunity due to prior chemotherapy and monoclonalantibody therapy."Benedek I, et al. SEVERE CASE OF HEPATITIS C INFECTION AT AFOLLICULAR NON-HODGKIN LYMPHOMA PATIENT UNDER RITUXIMABMAINTENANCE THERAPY. 15th Congress of the European HaematologyAssociation : abstr. 1617, 10 Jun 2010. Available from: URL: http://eha.eurocongres.com/15th - Romania 803026541
1
Reactions 17 Jul 2010 No. 13100114-9954/10/1310-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
